Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists hunt for biomarkers to personalize ventilator care in ARDS

NCT ID NCT07380997

Knowledge-focused Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study will analyze blood and sputum samples from 411 adults with acute respiratory distress syndrome (ARDS) who are on ventilators. Researchers will look for patterns in microbes, metabolites, and gene activity to see if they can predict how well patients respond to ventilation and their 28-day survival. The goal is to find biomarkers that could one day guide personalized ventilator strategies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could identify molecular markers that help doctors personalize ventilator settings for ARDS patients, potentially improving survival.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to any direct clinical changes, and the findings might not apply to all ARDS patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 411 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients admitted to the intensive care unit(s) at Ruijin Hospital who require ventilation for ARDS (Berlin definition) or acute respiratory failure without ARDS, and are eligible for biospecimen collection (plasma from residual clinical venous blood and sputum) and clinical data collection

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written and dated informed consent provided. * Age ≥18 years. * ARDS diagnosed according to the 2012 Berlin definition. * Clinically stable * eligible for enrollment after 12-24 hours of stability. * Baseline oxygenation index (PaO2/FiO2 ≤300 mmHg) * No history of major chronic lung disease and no history of immunosuppression. * Able to comply with study procedures, including collection of blood/plasma and sputum samples and clinical data. Exclusion Criteria: * Severe autoimmune disease or active systemic inflammatory disease. * Severe hepatic dysfunction or renal failure requiring dialysis. * Invasive mechanical ventilation for \>36 hours prior to enrollment, or death prior to enrollment. * Expected death within 24 hours of admission or inability to complete study-related assessments due to imminent death. * Presence of a cardiac pacemaker or other implanted electronic device that may affect respiratory function assessment. * Pregnant or breastfeeding women. * Severe allergy to materials required for sample collection or other relevant contraindications. * Severe psychiatric illness or inability to cooperate with study procedures. * Prior participation in other interventional clinical trials that could affect interpretation of study results. * Refusal of consent or withdrawal of informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute respiratory distress syndrome (ARDS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute respiratory distress syndrome adult acute respiratory distress syndrome metabolic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute respiratory distress syndrome (ARDS) Metabolomics Microbiome dysbiosis Multiomics analysis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.